ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products.

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.

DALLAS, June 19, 2024 /PRNewswire/ — 4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary Truss Implant Technology™, announced the initial launch of the newest addition to the company’s portfolio, the Cervical Spine Truss System Integrated Plating Solution (CSTS-IPS). The first procedures were performed by Kris Parchuri, DO, orthopedic spine surgeon at Spine & Orthopedic Specialists in Tulsa, OK and Jason Alder, MD, Director of Spinal Surgery at Baylor Scott & White Medical Center in Frisco, TX.

The designation recognises the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease.

SHANGHAI, June 17, 2024 /PRNewswire/ — MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic valve implantation (TAVI) device, the VitaFlow LibertyTM Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow LibertyTM), has received EU CE-MDR certification. This certification highlights VitaFlow LibertyTM as a pioneering TAVI solution, that sets a new benchmark in transcatheter heart valve treatments.

Philips (NYSE:PHG) announced today that it launched its now FDA-cleared Zenition 90 motorized mobile C-arm system.

Leuko, founded by a research team at MIT, is giving doctors a noninvasive way to monitor cancer patients’ health during chemotherapy — no blood tests needed.

This marks a significant advancement in the international progress of VenusP-Valve and represents another milestone following its CE MDR approval in April 2022.